Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Top Cited Papers
- 1 February 2004
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 126 (2) , 402-413
- https://doi.org/10.1053/j.gastro.2003.11.014
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Infliximab in Crohn's Disease: First Anniversary Clinical ExperienceAmerican Journal of Gastroenterology, 2000
- Clinical Experience With Infliximab Therapy in 100 Patients With Crohn's DiseaseAmerican Journal of Gastroenterology, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumour necrosis factor α and interleukin 1β in relapse of Crohn's diseaseThe Lancet, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel diseaseGastroenterology, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Tumour necrosis factor alpha in stool as a marker of intestinal inflammationThe Lancet, 1992
- Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestineClinical and Experimental Immunology, 1990
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989